These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3266444)

  • 21. Changes in lymphocyte subsets following administration of interleukin 2 and cyclophosphamide in mice with transitional cell carcinoma.
    Ikemoto S; Kamizuru M; Wada S; Asai Y; Kishimoto T
    Oncol Res; 1997; 9(2):71-5. PubMed ID: 9167188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The study of infiltrating lymphocytes in the tissues of bladder carcinoma].
    Fujimoto Y; Hasegawa Y; Kato N; Sakai S; Kuriyama M; Kawada Y; Nishiura T; Takeuchi T; Isogai K
    Hinyokika Kiyo; 1983 Sep; 29(9):1037-45. PubMed ID: 6610297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
    Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
    J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
    Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
    Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.
    Mazzolini G; Alfaro C; Sangro B; Feijoó E; Ruiz J; Benito A; Tirapu I; Arina A; Sola J; Herraiz M; Lucena F; Olagüe C; Subtil J; Quiroga J; Herrero I; Sádaba B; Bendandi M; Qian C; Prieto J; Melero I
    J Clin Oncol; 2005 Feb; 23(5):999-1010. PubMed ID: 15598979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Continuous arterial infusion therapy of recombinant interleukin-2 and cyclophosphamide in hepatoma and liver metastasis].
    Hayakawa K; Fukushima T; Seito D; Asakura Y; Yamanaka Y; Morita T; Sasaki M; Konn M; Ono K
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2842-4. PubMed ID: 2551226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y; Okada Y; Terachi T; Yoshida O
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
    Yu DS; Lee CF; Hsieh DS; Chang SY
    Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conservative management of low risk superficial bladder tumors.
    Pruthi RS; Baldwin N; Bhalani V; Wallen EM
    J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin 2. A pathologic and immunophenotypic study.
    Valente G; De Stefani A; Jemma C; Giovarelli M; Geuna M; Cortesina G; Forni G; Palestro G
    Mod Pathol; 1990 Nov; 3(6):702-8. PubMed ID: 2263594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2.
    Tubaro A; Stoppacciaro A; Velotti F; Bossola PC; Cusumano G; Vicentini C; De Carli P; Ruco L; Santoni A; Cancrini A
    Eur Urol; 1995; 28(4):297-303. PubMed ID: 8575496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A phase I study of recombinant interleukin 2 (S6820)].
    Takaku F
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3271-6. PubMed ID: 3058043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.